CRISPR-Cas-Based Genome Editing for Treating Human Diseases - Part B

CRISPR-Cas-based genome editing for treating human diseases part B represents CRISPR-Cas systems for genome editing. Currently, CRISPR-Cas systems are proven a key technology for targeted genome editing which is acting as a simple, rapid, and cost-effective solution. CRISPR-Cas9 system is being used in microbial genome editing, mammalian genome editing, disease models, and many. It has shown potential in human disease treatment. However, it is not easy to find CRISPR-Cas systems genome editing in a single source. This volume offers CRISPR-Cas systems for metabolic disorders, retinal disease cataract and blindness, muscular dystrophy, cardiac disease, diabetes, liver disease, lung disease, kidney diseases, rare disease, heredity disease, neurological disorders and CRISPR challenges in clinical developments. This volume highlights a number of aspects of the CRISPR-Cas sytems that can help the basic understanding of students, researchers, clinicians, entrepreneurs, and stakeholders to perform their research with great interest. To provide CRISPR-Cas systems for metabolic disorders, retinal disease cataract and blindnessTo offer muscular dystrophy, cardiac disease, diabetes, liver diseaseTo offer lung disease, kidney diseases, rare disease, heredity disease, neurological disorders and CRISPR challenges in clinical developments